---

Highlights of January 2019

• Aurobindo to buy 7 oncology injectables from Spectrum Pharma in US$300 Million deal.
• Glenmark inks pact with South Korea’s Yuhan Corp to commercialize Ryaltris.
• Cadila Pharma inks pact with Norwegian start-up Serca Pharmaceuticals to develop new treatment for heart patients.
• Bio-Thera Reaches Licensing Agreement with Cipla for Bevacizumab Biosimilar.
• Strides Pharma Science Limited (Strides) to acquire 100% stake in Vensun Pharmaceuticals, Inc (a US-based Generics Company).
• WIRB-Copernicus Group snaps up Velos eResearch for undisclosed price.
• Janssen plunks down US$100 Million for MeiraGTx’s retinal disease gene therapy pipeline.
• Neurocrine pays Voyager US$165 Million for neurological gene therapies.
• Aldeyra boosts eye disease pipeline with US$10 Million Helio Vision buy.
• Abcam Expands Custom Services Capabilities with the Acquisition of Calico Biolabs.
• Celgene strikes Obsidian deal to boost CAR-T options with US$80 Million upfront.
• Pfizer inks collaboration deal to use CytoReason's cell-centered models of immune system.
• MabSpace and HJB merge to form biotherapeutics company Transcenta.
• Gilead adds another shot on the NASH goal with US$785 Million Yuhan pact.
• Mylan snaps up HIV-focused South African facility from Ascendis for US$9.4 Million.

Updates at Aagami: 

• Aagami completed JPM week in San Francisco; 45+ one-on-one global partnering related strategic meetings.
• Aagami CEO to travel to India from US on a business trip in Feb 2019

Release Date: 10 January 2019